These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32639512)
1. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation. Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
3. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379 [TBL] [Abstract][Full Text] [Related]
4. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512 [TBL] [Abstract][Full Text] [Related]
5. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119 [TBL] [Abstract][Full Text] [Related]
7. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474 [TBL] [Abstract][Full Text] [Related]
8. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158 [TBL] [Abstract][Full Text] [Related]
9. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163 [TBL] [Abstract][Full Text] [Related]
10. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436 [TBL] [Abstract][Full Text] [Related]
11. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. Auer E; Frey S; Kaesmacher J; Hakim A; Seiffge DJ; Goeldlin M; Arnold M; Fischer U; Jung S; Meinel TR J Neurol; 2019 Sep; 266(9):2263-2272. PubMed ID: 31165232 [TBL] [Abstract][Full Text] [Related]
12. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
13. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489 [TBL] [Abstract][Full Text] [Related]
14. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database. Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991 [TBL] [Abstract][Full Text] [Related]
15. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130 [TBL] [Abstract][Full Text] [Related]
16. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337 [TBL] [Abstract][Full Text] [Related]
17. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496 [TBL] [Abstract][Full Text] [Related]
18. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN. van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869 [TBL] [Abstract][Full Text] [Related]
19. Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Yoshida R; Morishima I; Takagi K; Morita Y; Tsuboi H; Murohara T Circ J; 2018 Jul; 82(8):2016-2024. PubMed ID: 29863094 [TBL] [Abstract][Full Text] [Related]
20. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]